Dr Munitta Muthana, BSc Hon, PhD



Academic Unit of Respiratory Medicine
Department of Infection and Immunity
K Floor
The University of Sheffield Medical School
Beech Hill Road
Sheffield S10 2RX
United Kingdom

Telephone: +44 (0)114 226 5852
Fax: +44 (0)114 271 3892
Email: m.muthana@sheffield.ac.uk


I joined The University of Sheffield in 2002 as post-doctoral scientist in the Immunobiology Research Unit. From 2005 I held a research position in the Tumour Targeting Group where I was awarded funding as an independent researcher from the Prostate Cancer Charity (2007) and the Medical Research Council (2010). In 2011 I was appointed as a non-clinical lecturer in the Department of Infection and Immunity.

Research Interests

My research focuses on the role of innate immune cells like macrophages and dendritic cells in diseases including cancer and rheumatoid arthritis.  Recently, I have used my knowledge of this area to develop innovative cell-based methods to target anticancer thereapy to tumours.  For example, I have devised a way to use macrophages to deliver large quantities of cancer-killing virus to both primary and secondary tumours simultaneously (click here).  My group is also interested in improving the delivery of therapies to diseased tissue using a nanomagnetic targeting approach.

Professional activities

  • American Association of Cancer Research (AACR)
  • British Society of immunology (BSI)
  • European Macrophage and Dendritic Cell Society and British Society of Immunology.

Current projects

  • Characterisation of infiltrating subsets of monocytes/macrophages in diseased tissues including the arthritic joint and the tumour microenvironment
  • Role of epigenetic factors in arthritis
  • Targeting viral therapies to diseased tissues using nanomagnet technology
  • Using combination therapies to target tumours

Key Publications

  1. Vitamin d deficiency and exogenous vitamin d excess similarly increase diffuse atherosclerotic calcification in apolipoprotein e knockout mice.  Ellam T, Hameed A, Ul Haque R, Muthana M, Wilkie M, Francis SE, Chico TJ.  PLoS One. 2014 Feb 19;9(2):e88767.
  2. A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice. Chen YY, Brown NJ, Jones R, Lewis CE, Mujamammi AH, Muthana M, Seed MP, Barker MD. Angiogenesis. 2014 Jan;17(1):207-19. doi: 10.1007/s10456-013-9389-y. Epub 2013 Oct 16.
  3. The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes. Hawtree S, Muthana M, Wilson AG. Biochem Soc Trans. 2013 Jun;41(3):783-8.
  4. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Muthana M, Rodrigues S, Chen YY, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE. Cancer Res. 2013 Jan 15;73(2):490-5.
  5. Khat (Catha edulis) alters the phenotype and anti-microbial activity of peripheral blood mononuclear cells. Murdoch C, Aziz HA, Fang HY, Jezan H, Musaid R, Muthana M. J Ethnopharmacol. 2011 Dec 8;138(3):780-7.
  6. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M, Lewis CE. J Immunol. 2011 Apr 1;186(7):4183-90.
  7. Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE, Byrne HM. Cancer Res. 2011 Apr 15;71(8):2826-37.
  8. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Muthana M, Giannoudis A, Scott SD, Fang HY, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B, Mistry R, Hamdy F, Brown NJ, Georgopoulos L, Hoskin P, Essand M, Lewis CE, Maitland NJ. Cancer Res. 2011 Mar 1;71(5):1805-15.
  9. Tumour infiltrating host cells and their significance for hyperthermia. Muthana M, Multhoff G, Pockley AG. Int J Hyperthermia. 2010;26(3):247-55.
  10. The role of myeloid cells in the promotion of tumour angiogenesis. Murdoch C, Muthana M, Coffelt SB, Lewis CE. Nat Rev Cancer. 2008 Aug;8(8):618-31.
  11. A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Muthana M, Scott SD, Farrow N, Morrow F, Murdoch C, Grubb S, Brown N, Dobson J, Lewis CE. Gene Ther. 2008 Jun;15(12):902-10.
  12. The dual immunoregulatory roles of stress proteins. Pockley AG, Muthana M, Calderwood SK. Trends Biochem Sci. 2008 Feb;33(2):71-9.
  13. A non-receptor-mediated mechanism for internalization of molecular chaperones. Pockley AG, Fairburn B, Mirza S, Slack LK, Hopkinson K, Muthana M. Methods. 2007 Nov;43(3):238-44.
  14. Administration of the stress protein gp96 prolongs rat cardiac allograft survival, modifies rejection-associated inflammatory events, and induces a state of peripheral T-cell hyporesponsiveness. Slack LK, Muthana M, Hopkinson K, Suvarna SK, Espigares E, Mirza S, Fairburn B, Pockley AG. Cell Stress Chaperones. 2007 Spring;12(1):71-82.